Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,77%
1 084,46
+8,33
+0,77%
—1 076,131 079,891 086,381 079,89——
SIXC
Communications
SIXC
Communications
SIXC
-0,25%
605,21
-1,53
-0,25%
—606,74606,74607,90605,93——
SIXE
Energy
SIXE
Energy
SIXE
-0,02%
1 248,59
-0,23
-0,02%
—1 248,821 246,371 246,371 239,08——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,56%
1 733,98
+9,62
+0,56%
—1 724,361 733,021 740,961 733,02——
SIXM
Financials
SIXM
Financials
SIXM
-0,12%
634,80
-0,79
-0,12%
—635,59635,08636,46634,31——
SIXR
Staples
SIXR
Staples
SIXR
-0,08%
842,47
-0,68
-0,08%
—843,15842,50844,00841,14——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,15%
216,61
+0,32
+0,15%
—216,29216,29216,91216,29——
SIXT
Technology
SIXT
Technology
SIXT
+1,43%
3 310,16
+46,75
+1,43%
—3 263,413 296,253 307,673 295,42——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,37%
942,74
+3,50
+0,37%
—939,24941,57943,96940,38——
SIXV
Health care
SIXV
Health care
SIXV
+0,15%
1 464,82
+2,26
+0,15%
—1 462,561 465,031 470,171 465,03——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,80%
2 399,54
+19,14
+0,80%
—2 380,402 394,922 412,132 394,92——
Q1 2026 earnings • 11:00 PM today
See details
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
25,02 US$
+0,83%
(+0,20) 1D
5 მაი, 09:54:42 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
24,96 US$
High
25,32 US$
Low
24,94 US$
Mkt. cap
2,46 მლრდ.
Avg. vol.
1,89 მლნ.
Volume
38,34 ათ.
52-wk high
42,37 US$
52-wk low
18,29 US$
EPS
-5,83 US$
Beta
0,39
Shares outstanding
98,32 მლნ.
No. of employees
1 ათ.
News stories
From sources across the web
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOემილ კაკისი
Employees1,37 ათ.
Founded2010
HeadquartersNovato, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websiteultragenyx.com
Next call in 7:04:54
Today, 23:00
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-1,46 est.)USD
Revenue / Estimate
-/ (158,41 მლნ. est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
მარ. 2025
ივნ. 2025
სექ. 2025
დეკ. 2025
Revenue
139,29 მლნ.
166,50 მლნ.
159,93 მლნ.
207,28 მლნ.
Cost of goods sold
194,43 მლნ.
187,74 მლნ.
244,20 მლნ.
232,62 მლნ.
Cost of revenue
194,43 მლნ.
187,74 მლნ.
244,20 მლნ.
232,62 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87,80 მლნ.
86,65 მლნ.
86,62 მლნ.
87,94 მლნ.
Operating expense
87,80 მლნ.
86,65 მლნ.
86,62 მლნ.
87,94 მლნ.
Total operating expenses
282,23 მლნ.
274,38 მლნ.
330,82 მლნ.
320,56 მლნ.
Operating income
-142,94 მლნ.
-107,89 მლნ.
-170,89 მლნ.
-113,28 მლნ.
Other non operating income
837,00 ათ.
2,14 მლნ.
-1,04 მლნ.
-934,00 ათ.
EBT including unusual items
-149,77 მლნ.
-114,00 მლნ.
-179,54 მლნ.
-127,69 მლნ.
EBT excluding unusual items
-149,61 მლნ.
-114,00 მლნ.
-180,22 მლნ.
-127,17 მლნ.
Income tax expense
1,31 მლნ.
947,00 ათ.
873,00 ათ.
870,00 ათ.
Effective tax rate
-0,87%
-0,83%
-0,49%
-0,68%
Other operating expenses
-
-
-
-
Net income
-151,08 მლნ.
-114,95 მლნ.
-180,41 მლნ.
-128,56 მლნ.
Net profit margin
-108,46%
-69,04%
-112,81%
-62,02%
Earnings per share
-1,57
-1,17
-1,81
-1,29
Interest and investment income
6,83 მლნ.
5,79 მლნ.
5,86 მლნ.
6,51 მლნ.
Interest expense
-14,34 მლნ.
-14,04 მლნ.
-14,15 მლნ.
-19,47 მლნ.
Net interest expenses
-7,51 მლნ.
-8,25 მლნ.
-8,28 მლნ.
-12,96 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-133,95 მლნ.
-99,27 მლნ.
-162,28 მლნ.
-104,50 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer